PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014)

Abbreviated Name
PCA3 Ref Set App-T2 ERG-Sanda (2014)
Lead Investigator
Sanda, MartinEmory University
Coordinating Investigator
Feng, Ziding Fred Hutchinson Cancer Center
Involved Investigators

Abstact

Aims

Primary Specific Aims Aim 1:   To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of histologically clinically significant prostate cancer among men without prior evidence of prostate cancer Secondary Aims Aim 1:   To evaluate the sensitivity, specificity, PPV, NPV and absolute risk prediction by T2:erg/PCA3 combined and multiplexed with other biomarkers and clinical variables in the detection of histologically clinically significant prostate cancer Aim 2:    To validate the performance of urinary T2:erg in a multiplex model in combination with PCA3 predicting the diagnosis of ANY prostate cancer Aim 3:    To investigate whether the multiplex model performance is improved by addition of % free PSA, PSAV, -2proPSA, and other markers in development Aim 4:   To evaluate the correlation between urinary and tissue based T2:erg and prostate biopsy tumor grade

Analytic Method

Transcription mediated amplification based assay

Biomarkers

Data Collections

  • No data available at this time for this protocol
Protocol ID
376
Protocol Type
Reference Set
Field of Research
Genomics
Collaborative Group
Prostate and Urologic Cancers Research Group
Cancer Types
  • Malignant neoplasm of prostate
Phased Status
2

Associated Forms